Inmed pharmaceuticals receives nasdaq notification regarding minimum bid price compliance

Vancouver, british columbia, july 12, 2022 (globe newswire) -- inmed pharmaceuticals inc. (“inmed” or the “company”) (nasdaq: inm), a research, development, manufacturing corporation specializing in the commercialization of rare cannabinoids, announces that, as previously disclosed pursuant to a form 8-k filed with the securities exchange commission on june 21, 2022, the company received written notice from the listing qualifications department staff of the nasdaq capital market (“nasdaq”) notifying it that the closing bid price of the company's common shares over a period of 30 consecutive trading days was below the minimum $1.00 per share requirement for continued listing on the nasdaq under nasdaq listing rule 5550(a)(2).
INM Ratings Summary
INM Quant Ranking